scholarly article | Q13442814 |
P819 | ADS bibcode | 2011PLoSO...624782P |
P356 | DOI | 10.1371/JOURNAL.PONE.0024782 |
P932 | PMC publication ID | 3172285 |
P698 | PubMed publication ID | 21931852 |
P5875 | ResearchGate publication ID | 51655876 |
P2093 | author name string | David E Clements | |
George S Hui | |||
Kae M Pusic | |||
Axel Lehrer | |||
Caryn N Hashimoto | |||
Charmaine Aniya | |||
P2860 | cites work | ProPred: prediction of HLA-DR binding sites. | Q52049897 |
Cell lines derived from late embryonic stages of Drosophila melanogaster | Q52834135 | ||
Production of pathogenic antibodies: cognate interactions between autoimmune T and B cells. | Q53939339 | ||
Antigen-specific interaction between T and B cells | Q59063745 | ||
A single 10-residue pre-S(1) peptide can prime T cell help for antibody production to multiple epitopes within the pre-S(1), pre-S(2), and S regions of HBsAg | Q68994154 | ||
Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults | Q28749215 | ||
Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria | Q33281394 | ||
The importance of human FcgammaRI in mediating protection to malaria | Q33285037 | ||
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya | Q33415066 | ||
Growth-inhibitory antibodies are not necessary for protective immunity to malaria infection | Q33613813 | ||
Suppressive and additive effects in protection mediated by combinations of monoclonal antibodies specific for merozoite surface protein 1 of Plasmodium yoelii. | Q33711883 | ||
Passive immunization with antibodies against three distinct epitopes on Plasmodium yoelii merozoite surface protein 1 suppresses parasitemia | Q33759208 | ||
Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria | Q33852294 | ||
Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys | Q34003578 | ||
Linkage of exogenous T-cell epitopes to the 19-kilodalton region of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) can enhance protective immunity against malaria and modulate the immunoglobulin subclass response to MSP1(19). | Q34003924 | ||
Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. | Q34003987 | ||
Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial | Q34006332 | ||
New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1 | Q34290768 | ||
Generalized immunological recognition of the major merozoite surface antigen (gp195) of Plasmodium falciparum | Q34298109 | ||
Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria | Q34620173 | ||
Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity | Q34975629 | ||
A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. | Q35463512 | ||
Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies | Q35762375 | ||
Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. | Q36368911 | ||
Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies | Q36380869 | ||
The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine | Q36398927 | ||
Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities | Q36825059 | ||
Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria | Q37146236 | ||
Inhibitory antibodies specific for the 19-kilodalton fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semi-immune individuals in Vietnam | Q37355849 | ||
The 3' portion of the gene for a Plasmodium yoelii merozoite surface antigen encodes the epitope recognized by a protective monoclonal antibody | Q37483845 | ||
A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth | Q38938589 | ||
Biological activities of anti-merozoite surface protein-1 antibodies induced by adjuvant-assisted immunizations in mice with different immune gene knockouts | Q39085980 | ||
Plasmodium falciparum anti-MSP1-19 antibodies induced by MSP1-42 and MSP1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes | Q39085988 | ||
Immunogenicity of the C-terminal 19-kDa fragment of the Plasmodium falciparum merozoite surface protein 1 (MSP1), YMSP1(19) expressed in S. cerevisiae | Q39086004 | ||
Induction of antibodies to the Plasmodium falciparum merozoite surface protein-1 (MSP1) by cross-priming with heterologous MSP1s | Q39086009 | ||
Serum from Pf195 protected Aotus monkeys inhibit Plasmodium falciparum growth in vitro | Q39086075 | ||
T- and B-cell recognition of hepatitis B viral antigens | Q39579867 | ||
In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodium falciparum merozoite surface protein 1 in the baculovirus-silkworm system | Q39655089 | ||
Identification of T cell epitopes on the 33-kDa fragment of Plasmodium yoelii merozoite surface protein 1 and their antibody-independent protective role in immunity to blood stage malaria | Q40720795 | ||
Definition of T cell epitopes within the 19 kDa carboxylterminal fragment of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) and their role in immunity to malaria | Q41028358 | ||
Regulated expression allows high level production and secretion of HIV-1 gp120 envelope glycoprotein in Drosophila Schneider cells | Q41698821 | ||
Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages | Q41835030 | ||
A protective monoclonal antibody recognizes a variant-specific epitope in the precursor of the major merozoite surface antigen of the rodent malarial parasite Plasmodium yoelii | Q42074466 | ||
The three major antigens on the surface of Plasmodium falciparum merozoites are derived from a single high molecular weight precursor. | Q42937100 | ||
Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with a | Q44078968 | ||
Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya | Q46884256 | ||
Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa | Q47309532 | ||
Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro | Q47845842 | ||
Fine specificity of neonatal lymphocytes to an abundant malaria blood-stage antigen: epitope mapping of Plasmodium falciparum MSP1(33). | Q47860963 | ||
Identification of frequently recognized dimorphic T-cell epitopes in plasmodium falciparum merozoite surface protein-1 in West and East Africans: lack of correlation of immune recognition and allelic prevalence | Q47886473 | ||
Fragments of the polymorphic Mr 185,000 glycoprotein from the surface of isolated Plasmodium falciparum merozoites form an antigenic complex | Q47887386 | ||
Primary structure of the precursor to the three major surface antigens of Plasmodium falciparum merozoites | Q47902824 | ||
The role of the 19-kDa region of merozoite surface protein 1 and whole-parasite-specific maternal antibodies in directing neonatal pups' responses to rodent malaria infection | Q47969981 | ||
Expression of an immunologically reactive merozoite surface protein (MSP-1(42)) in E. coli | Q47998752 | ||
Nucleotide sequence analysis and epitope mapping of the merozoite surface protein 1 from Plasmodium chabaudi chabaudi AS. | Q47998819 | ||
Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1. | Q47999462 | ||
Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese vi | Q48000659 | ||
Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria | Q48000982 | ||
Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity | Q48027524 | ||
Dimorphic Plasmodium falciparum merozoite surface protein-1 epitopes turn off memory T cells and interfere with T cell priming | Q48027581 | ||
Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine. | Q48030282 | ||
Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development | Q48035058 | ||
Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains | Q48202726 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | e24782 | |
P577 | publication date | 2011-01-01 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | T cell epitope regions of the P. falciparum MSP1-33 critically influence immune responses and in vitro efficacy of MSP1-42 vaccines | |
P478 | volume | 6 |
Q37264673 | A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies |
Q28730779 | A hybrid multistage protein vaccine induces protective immunity against murine malaria |
Q35010158 | Antibody and T cell responses in reciprocal prime-boost studies with full-length and truncated merozoite surface protein 1-42 vaccines |
Q36155945 | Evaluation of the immunogenicity and vaccine potential of recombinant Plasmodium falciparum merozoite surface protein 8. |
Q39403308 | Generation, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP119. |
Q36882512 | Humoral and cellular immunity to Plasmodium falciparum merozoite surface protein 1 and protection from infection with blood-stage parasites |
Q89559305 | Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial |
Q36412687 | Impact of pre-existing MSP1(42)-allele specific immunity on potency of an erythrocytic Plasmodium falciparum vaccine |
Q36615170 | Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine |
Q40592413 | Longevity of Genotype-Specific Immune Responses to Plasmodium falciparum Merozoite Surface Protein 1 in Kenyan Children from Regions of Different Malaria Transmission Intensity |
Q39246146 | Reduced immunogenicity of Plasmodium falciparum gamete surface antigen (Pfs48/45) in mice after disruption of disulphide bonds - evaluating effect of interferon-γ-inducible lysosomal thiol reductase. |
Search more.